Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Fibrolamellar carcinoma


Other Names for this Disease
  • 9q31.1q31.3 microdeletion syndrome
  • Del(9)(q31.1q31.3)
  • Eosinophilic glassy cell hepatoma
  • Eosinophilic hepatocellular carcinoma with lamellar fibrosis
  • Fibrolamellar hepatocellular carcinoma
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might fibrolamellar carcinoma be treated?

The standard treatment for fibrolamellar carcinoma (FLC) is surgical resection. Due to the rarity of the condition, there is limited information to support the use of other treatment options and there is no standard chemotherapy regimen. However, other treatments may be considered if surgical resection isn't an option. For example, liver transplantation may be considered in patients who are not candidates for partial resection (removing a portion of the liver).[1][2]

Medscape Reference's Web site offers more specific information on the treatment and management of FLC. Please click the link to access this resource. 
Last updated: 4/23/2015

References
  1. Michael A Choti, MD, MBA, FACS. Fibrolamellar Carcinoma. Medscape Reference. August 2015; http://emedicine.medscape.com/article/278354-overview.
  2. Lim II, Farber BA, LaQuaglia MP. Advances in fibrolamellar hepatocellular carcinoma: a review. Eur J Pediatr Surg. December 2014; 24(6):461-466.


GARD Video Tutorial

  • Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.

    Finding Treatment Information

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Fibrolamellar carcinoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
  • The Fibrolamellar Tissue Repository is a tissue bank for fibrolamellar samples obtained during surgery. This repository is a resource for Rockefeller University and other approved academic institutions who are interested in performing scientific research that will improve the diagnosis, treatment, and understanding of this rare disease.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Sorafenib
Trade Name
(Manufacturer Name)
Nexavar®
(Bayer HealthCare Pharmaceuticals)
Indication
The FDA has approved this product to be used in this manner.
Treatment of unresectable hepatocellular carcinoma
More Information about this product Drug Information Portal

Other Names for this Disease
  • 9q31.1q31.3 microdeletion syndrome
  • Del(9)(q31.1q31.3)
  • Eosinophilic glassy cell hepatoma
  • Eosinophilic hepatocellular carcinoma with lamellar fibrosis
  • Fibrolamellar hepatocellular carcinoma
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.